RG 6016

Drug Profile

RG 6016

Alternative Names: ORY-1001; RG 6016; RO 7051790

Latest Information Update: 12 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ministry of Economy and Competitiveness; Oryzon
  • Developer Oryzon; Roche
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Phase I Small cell lung cancer
  • Preclinical Acute biphenotypic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 07 Mar 2018 Pharmacodynamics data from preclinical studies in Leukaemia released by Oryzon
  • 05 Mar 2018 Adverse events data from a phase I/IIa trial in Leukaemia released by Oryzon
  • 20 Feb 2018 Oryzon plans clinical trials for Small cell lung cancer and Leukaemia in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top